The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma.
暂无分享,去创建一个
M. Gurnell | I. Mackenzie | H. Simpson | K. Balan | K. Chatterjee | M. Brown | Isla S. Mackenzie | Helen Simpson | Morris J. Brown
[1] M. J. Ashby,et al. AT2 Receptor Stimulation May Halt Progression of Pheochromocytoma , 2006, Annals of the New York Academy of Sciences.
[2] J. Carrasquillo,et al. Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites , 2006, Nuclear medicine communications.
[3] Eva Forssell-Aronsson,et al. Importance of Vesicle Proteins in the Diagnosis and Treatment of Neuroendocrine Tumors , 2004, Annals of the New York Academy of Sciences.
[4] J. Carrasquillo,et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. , 2003, The Journal of clinical endocrinology and metabolism.
[5] M. Walther,et al. Biochemical diagnosis of pheochromocytoma: which test is best? , 2002, JAMA.
[6] H. Neumann,et al. Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. , 2002, Radiology.
[7] Graeme Eisenhofer,et al. 6-[18F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma , 2001, Hypertension.